{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-407696","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2026-09-29T20:45:42+00:00","discovered_at":"2026-09-29T20:47:00.397032+00:00","generated_at":"2026-10-12T13:51:54.313917+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Phathom starts patient screening in Phase 3 pHalcon-NERD-302 testing as-needed VOQUEZNA for Non-Erosive GERD","bullets":["Phathom announced initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study of as-needed VOQUEZNA (vonoprazan) 10 mg in adults with Non-Erosive GERD.","Topline results are expected in the first quarter of 2028; if successful, the study would support a regulatory submission for a VOQUEZNA label expansion.","The trial is expected to enroll approximately 500 adults with heartburn at least four days per week at roughly 80 U.S. sites.","After a four-week open-label run-in, patients are randomized 1:1 to VOQUEZNA 10 mg or placebo as-needed for 24 weeks, with the primary endpoint assessed at Week 12."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-407696","json":"https://secwatch.observer/filing/0001193125-26-407696.json","markdown":"https://secwatch.observer/filing/0001193125-26-407696.md","text":"https://secwatch.observer/filing/0001193125-26-407696.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312526407696/0001193125-26-407696-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312526407696/d22070d8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:51:54.313917+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}